Panoro Minerals has signed a five-year agreement with the Cochapata community granting surface access for mining activities at the Cotabambas Copper/Gold/Silver Project in Peru. This deal enables Panoro to proceed with extensive drilling at the North Pit to expand and upgrade its high-grade mineral resources, supporting upcoming feasibility studies. The agreement also includes commitments to local education, employment, and infrastructure, reflecting strong community alignment. Panoro plans to update its resource estimates in early 2027 and aims to complete economic assessments by the end of 2027.
Panoro Minerals' long-term access agreement at Cotabambas provides context for Basic Materials sector activity on Pluang. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 06, 2026 03:02 WIB: Among 38 priced US stocks, 20 rose and 18 fell. Notable movers include FMC Corp at USD 8.98 with a 6.46% increase and a typical hold time of 67 days, Nucor Corporation at USD 251.00 up 4.41% with a 78-day hold, and Freeport-McMoRan Inc at USD 71.99 rising 3.88% with a 69-day hold and Pluang order activity showing 58% Sell and 42% Buy.
Revvity's stock has surged 56.1% year-to-date, outperforming its industry and the S&P 500, driven by an 11% organic revenue growth in diagnostics, especially in reproductive health and immunodiagnostics. Analysts from William Blair and Zacks have upg...
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...
Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...
